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1. Introduction
  Myocardial hypertrophy is a compensatory response 
of the heart to the pressure or volume load, and 1/3 of 
patients with hypertension may develop the left ventricular 
hypertrophy, which is the major risk factor for sudden death 
and coronary heart disease[1]. The pathological mechanism 
underlying the left ventricular hypertrophy includes 
myocardial hypertrophy, fibrosis and collagen deposition, 
and the local manifestations are similar to symptoms of 
amassment disease in traditional Chinese medicine, which 
suggest that the left ventricular hypertrophy is the results 
of qi, blood, phlegm stagnation and stasis[2]. In this study, 
the pressure-overload left ventricular hypertrophy models 
established in Wistar rats were treated with Xinjikang, in 
a broader attempt to investigate the effects of Xinjikang on 
the left ventricular hypertrophy remodeling and myocardial 
activity in hypertensive rats.
  
2. Materials and methods
2.1. Experimental animals
  Sixty Wistar rats aged 6 months, weighing (220暲10) g, 
males or females, were provided by the Experimental 
Animal Center, Yuhuangding Hospital of Yantai, Yantai, 
Shandong Province, China. Rats were housed at (23暲3) 曟
, allowing free access to food and water. Experimental 
disposals were in strict accordance with the Guideline on 
Administration of Laboratory Animals.
2.2. Drugs and instruments
  Metoprolol tablet containing 50 mg metoprolol tartrate was 
provided by Wuxi Huarui Pharmaceutical Co., Ltd., Wuxi, 
Jiangsu Province, China. Xinjikang decoction was consisted 
of Radix Salviae miltiorrhiae 15 g, Radix Astragali 20 g, 
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Rhizoma Pinelliae Preparata 10 g, Radix Notoginseng 5 g, 
Concha Haliotidis 20 g, Fructrs Trichosanthis 12 g, Radix 
Acanthopanacis Bidentatae and chrysanthemum 12 g. Each 
mL decoction contained crude drug 1 g. Lipoperoxides 
(LPO) and superoxide dismustase (SOD) detection kits were 
provided by Nanjing Jiancheng Bioengineering Institute, 
Nanjing, Jiangsu Province, China.
2.3. Establishment of models
  The pressure-overload left ventricular hypertrophy models 
were established with the abdominal aortic coarctation 
method. In brief, rats were anesthetized with intraperitoneal 
chloral hydrate, after the skin was disinfected, an incision 
was made along the xiphoid process for laparotomy, 
peritoneum and other soft tissue were separated, exposing 
the abdominal aorta. Subsequently the abdominal aorta 
was clamped and occluded using a silver clip above 
renal artery. We reset abdominal organs and closed the 
abdominal cavity after no bleeding was observed. Rats were 
intramuscularly injected with penicillin to prevent infection 
at 3 d postoperatively and restored the feeding 6 h later. 
The models can be defined success when the cardiac mass 




  Sixty rats were randomly divided into four groups: A, B, C, 
D, with 15 rats in each group. A is control group (receiving 
no ligation or occlusion) and B is model group, rats in A and 
B groups were treated with physiological saline (1 mL/100 g) 
at 4 weeks after modeling; C is Xinjikang group (rats were 
intragastrically given Xinjikang 3 mL/kg per day, twice a 
day); D is metoprolol group (rats were intragastrically given 
metoprolol 80 mg/mL/kg per day, twice a day).
2.5. Main outcome measures
  Changes in caudal artery blood pressure were observed 
before treatment, and at 2, 4, 6 weeks after treatment. E/
A ratio (the ratio of the early to late ventricular filling 
velocities) was measured using color Doppler ultrasound 
examination before modeling, before and after treatment. 
After rats in each group were killed at 6 weeks after 
treatment,  cardiac muscle cells were stained by 
hematoxylin-eosin and morphological changes of myocardial 
tissue were observed under electron microscopy. Myocardial 
tissue was grinded and the supernatant was collected, LPO 
levels were determined by thiobarbituric acid reaction[3] 
and SOD activity was assayed with pyrogallol autoxidation 
method[4].
2.6. Statistical analysis
  Data were analyzed using SPSS 12.0 software (SPSS, 
Chicago, IL, USA) and measurement data were expressed as 
mean暲SD using the t-test. A P<0.05 value was considered 
statistically significant differences.
3. Results
3.1. Comparison of blood pressure of rat tail artery in four 
groups before and after treatment 
  
  The tail arterial pressure in B, C, D groups of rats was 
significantly increased compared with that in A group at 4 
weeks after modeling (P<0.05), and there was no significant 
difference among B, C, D groups (P>0.05). The tail arterial 
pressure in C and D groups of rats began to decreased at 2, 4, 
6 weeks after treatment, which was significantly lower than 
B group (P<0.05); at 6 weeks, no difference was observed in 
the tail arterial pressure of C and D groups of rats compared 
with A group (P>0.05; Table 1).
Table 1
Comparison of tail arterial pressure before and after treatment (mmHg).
Group 4 weeks after 
modeling
After treatment
2 weeks 4 weeks 6 weeks
A 110.82暲3.11 109.82暲3.264 113.80暲3.92 112.41暲3.25
B 142.73暲6.60* 153.13暲4.74 158.95暲4.55 165.09暲4.21
C 142.31暲4.70* 130.92暲4.11吤 122.50暲4.45吤 116.32暲4.45吤
D 140.20暲5.63* 127.13暲3.89吤 119.23暲3.64吤 113.91暲3.32吤
*P<0.01, vs. A group; 吤P<0.05, vs. B group. A: control group; B: model 
group; C: Xinjikang group; D: metoprolol group.
3.2. Comparison of E/A ratio in four groups before and after 
treatment 
  The E/A ratio showed no significant differences among four 
groups before modeling (P>0.05). At 4 weeks after modeling, 
the E/A ratio in B, C, D groups of rats was significantly lower 
in that in A group (P<0.05); at 6 weeks after treatment, the E/
A ratio in C and D groups of rats was significantly increased 
compared with B group (P<0.05; Table 2).
Table 2
Comparison of E/A ratio in each group at different time points.
Group Before modeling 4 weeks after 
modeling
6 weeks after 
treatment
A 1.12暲0.06 1.12暲0.08 1.12暲0.07
B 1.14暲0.06 0.84暲0.07* 0.75暲0.03*
C 1.13暲0.04 0.86暲0.05* 1.06暲0.06吤 
D 1.12暲0.05 0.87暲0.04* 0.97暲0.05 吤
*P<0.05, vs. A group; 吤P<0.05, vs. B group. A: control group; B: model 
group; C: Xinjikang group; D: metoprolol group.
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3.3. Changes in morphology of myocardial tissue
  In B group, myocardial fibers were thick and ruptured, 
myocardial cells showed focal or patch degeneration and 
became necrotic. In C group, myocardial cells presented 
mild degeneration and hypertrophy, nuclear morphology 
was slightly irregular, myocardial microvessels were normal, 
interstitial edema was evident, and myocardial fibers 
were not ruptured. In D group, myocardial fibers partially 
fractured, myocardial cells presented mild degeneration, 
occasional spotty necrosis, interstitial edema, and unclear 
boundaries with surrounding cells (Figure 1).
A                                 B                                 C                                   D
Figure 1. Morphological changes of myocardial tissue in 4 groups 
(Hematoxylin-eosin staining, 暳200).
A: control group; B: model group; C: Xinjikang group; D: metoprolol 
group.
3.4. Comparison of LPO level and SOD activity in four 
groups
  
  The SOD activity in myocardial tissue was significantly 
increased, while LPO levels were significantly reduced in C 
group after treatment, compared with B group (P<0.05). There 
was no significant difference in the SOD and LPO levels 
between C group and D group after treatment (P>0.05; Table 
3). 
Table 3
Comparison of LPO levels and SOD activity in four group.





*P<0.05, vs. A group; 吤P<0.05, vs. B group. A: control group; B: model 
group; C: Xinjikang group; D: metoprolol group.
4. Discussion
   Myocardial hypertrophy is the common pathological 
process of a series of cardiovascular diseases, and the 
adaptive pathological change caused by myocardial 
overload[5-7]. Early myocardial hypertrophy is a beneficial 
compensatory response, but long-term sustained 
hypertrophy leads to dilated cardiomyopathy. Therefore 
improvement of left ventricular hypertrophy is regarded a 
key target in the treatment of hypertension[6]. In this study, 
we established the left ventricular pressure overload model 
with abdominal aortic coarctation method to produce the 
left ventricular hypertrophy, which was similar to clinical 
hypertension-caused left ventricular hypertrophy.
  In the Xinjikang’s prescription, Radix Salviae Miltiorrhiae 
can dilate peripheral vessels, improve microcirculation 
and inhibit fibrosis, its component tanshinone栻-A has 
anti-myocardial ischemia/hypoxia, anti-thrombosis and 
myocardial calcium channel blocking effects in modern 
pharmacology studies[8-12]. Additionally protective effects 
against pituitrin-induced ischemic electrocardiography 
changes are definitely displayed[8]. Radix Astragali can 
dilute peripheral vessels, lower blood pressure, and reduce 
collagen content, thus preventing myocardial fibrosis. It is 
highly involved in the protection of cardiac myocardial cells 
under oxygen/glucose deprivation conditions, increment 
of intracellular mitochondria and glycogen granules, 
and enhancement of myocardial cell metabolism and 
compensatory ability[9]. Radix Acanthopanacis Bidentatae 
has diuretic, antihypertensive, and blood promoting effects, 
it also reduces blood viscosity, hematocrit and aggregation 
index[13-15]. Radix Notoginseng is capable of dilating blood 
vessels, lowering blood pressure and improving myocardial 
ischemia. The negative autorhythmicity and negative 
conduction of Radix Notoginseng are the pharmacological 
basis for antiarrhythmic effects[16,17]. Chrysanthemum 
contains glycosides, which functions to reduce blood 
pressure, increase coronary blood flow and raise hypoxia 
tolerance. Fructrs Trichosanthis can expand coronary artery, 
lower blood fat and improve myocardial ischemia. Concha 
Haliotidis has hepatoprotective effect. The combination 
of the aforementioned herbs can improve cardiovascular 
diastolic functions, lower blood pressure, reduce serum type 
III procollagen terminal peptide and hyaluronic acid levels, 
and improve blood rheology conditions, thus the heart may 
develop from a chronic stress state to a harmony state with 
abundant qi, blood, nutrition and energy[18-20].
  In this study, the blood pressure of rats showed no 
significant difference between C group and D group, where 
rats were treated by Xinjikang or metoprolol (P>0.05), 
indicating that Xinjikang can significantly reduce blood 
pressure levels. At 4 weeks after modeling, the E/A ratio 
in B, C, D groups of rats was significantly lower than that 
in A group. This evidence implies that pressure overload 
left ventricular diastolic functions have changed. The E/A 
ratio significantly increased in the C group after treatment, 
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suggesting that Xinjikang, similar to western medicine 
metoprolol, can improve ventricular diastolic functions. The 
hematoxylin-eosin staining results displayed that, after rats 
were treated with Xinjikang, cardiac muscle cell hypertrophy 
and mild degeneration were observed, cardiac muscle fibers 
were not ruptured, and nucleus morphology was slightly 
irregular under light microscope. These evidence supported 
that, Xinjikang can significantly attenuate myocardial 
injury, thus reversing myocardial parenchyma remodeling. 
Additionally the sharp decline of LPO level and significant 
increased SOD activity implicate the role of Xinjikang on 
improving metabolic disorder of oxygen free radicals, thus 
reversing the left ventricular hypertrophy .
  In summary, our findings show that Xinjikang can improve 
myocardial injury, restore myocardial parenchyma and 
myocardial interstitial remodeling functions, thus it has 
a potential positive effect for the treatment of the left 
ventricular hypertrophy. 
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